Vaccine Delivery Technologies
There are currently several factors that are creating pressure to improve delivery systems for vaccines. First, in the current regulatory environment, there is a growing requirement to develop vaccines that are very well defined in molecular terms. Thus, as opposed to using whole-inactivated pathogens presenting a complex range of antigens, most newly developed vaccines are rather based on selected target antigens. In some cases these may be single molecules, or even fragments thereof, derived from an infectious micro-organism, a tumour cell, an allergen or an auto-antigen. The target molecule may be administered as a purified protein or as a peptide(s), or may be expressed from plasmid DNA or a recombinant virus. Often, such molecular vaccines are poorly immunogenic, implying a need for an adjuvant, a specific formulation or a vector system of enhanced immunogenicity1. Second, although in the past most vaccines have been designed to stimulate antibody responses against surface molecules of bacteria or viruses, new generation vaccines are increasingly designed to elicit cellular immune responses, especially of the Th1 type. Such responses are considered paramount for targeting chronic infectious diseases that may have an intracellular stage (associated for example with HIV1, herpes viruses, hepatitis C virus, Helicobacter pylori, Plasmodium falciparum, Mycobacterium tuberculosis), but also for the development of therapeutic vaccines against cancer, autoimmune diseases or allergies2. New vaccines are also being developed to elicit mucosal immune responses in humans, for example to protect against pathogens such as influenza virus, HIV1, HSV or human oncogenic or wart-associated papilloma viruses. Unlike most of the traditional vaccines, these efforts require the recruitment of cellular or mucosal immune effector mechanisms and necessitate the exploration of new routes of administration, new formulations, and new adjuvant systems3. Third, improving vaccine administration generally, either for the physician, or more importantly for the customer, towards pain-free and safe needle-less devices is likely to represent a major driver in the future vaccine market.
- Intradermal (ID) delivery
- Disposable-syringe jet injectors
- Needle-free innovations
- Oral and sublingual technologies
- Intranasal and pulmonary technologies
Related Conference of Vaccine Delivery Technologies
7th International Conference on Vaccines, Immunology and Clinical Trials
Vaccine Delivery Technologies Conference Speakers
Recommended Sessions
- Bacterial Vaccines
- Chicken Pox (Varicella) Vaccines
- Current Research and Future Challenges
- Entrepreneurs Investment Meet
- Flu Vaccines
- Haemophilus Influenza Type b (Hib) Vaccines
- Hepatitis Vaccines
- Human Papillomavirus (HPV) Vaccines
- Immunization safety
- Maternal Immunity
- Meningococcal Vaccines
- Multiple Vaccines (or) Combination Vaccines
- Neonatal Vaccines
- Polio Vaccines
- PPSV (Pneumococcal Vaccines)
- Rotavirus (RV) Vaccines
- Smallpox Vaccines
- Standard Immunizations For Children
- Vaccine Adjuvants
- Vaccine Delivery Technologies
- Vaccine Production and Development
- Vaccine Storage and Handling
- Vaccines For Pregnant Women
Related Journals
Are you interested in
- Animal & Plant Derived Vaccines - Vaccine Immunology 2024 (France)
- Animal Models & Clinical Trials - Vaccine Immunology 2024 (France)
- Antibodies: Engineering & Therapeutics - Vaccine Immunology 2024 (France)
- Antiviral Therapies - Virology 2024 (Austria)
- Basic Immunology - Virology 2024 (Austria)
- Cancer, Malaria & TB Vaccines - Vaccine Immunology 2024 (France)
- Cellular Immunology & Latest Innovations - Vaccine Immunology 2024 (France)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Clinical Immunology - Virology 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- Combination & Conjugate Vaccines - Vaccine Immunology 2024 (France)
- COVID19 Vaccines - VACCINE CONGRESS 2024 (Spain)
- Current Research & Future Challenges - Vaccine Immunology 2024 (France)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- DNA & Synthetic Vaccines - Vaccine Immunology 2024 (France)
- Emerging Infectious Diseases and Global Health - VACCINES WORLD 2024 (Canada)
- Emerging Viral Diseases - Virology 2024 (Austria)
- Epidemiology and Public Health - Virology 2024 (Austria)
- Ethical and Societal Aspects of Vaccination - VACCINES WORLD 2024 (Canada)
- Fish & Poultry Vaccines - Vaccine Immunology 2024 (France)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- Geriatric Immunization - Vaccine Immunology 2024 (France)
- Geriatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Global Vaccine Access - VACCINE CONGRESS 2024 (Spain)
- HIV Vaccines - Vaccine Immunology 2024 (France)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunization in Special Populations - VACCINES WORLD 2024 (Canada)
- Immunodiagnostics and Monitoring Immune Responses - VACCINES WORLD 2024 (Canada)
- Immunogenetics and Genomics - Virology 2024 (Austria)
- Immunogenetics and Personalized Vaccinology - VACCINES WORLD 2024 (Canada)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunology of Vaccines - VACCINE CONGRESS 2024 (Spain)
- Immunometabolism - Virology 2024 (Austria)
- Immunopathology and Host-Pathogen Interactions - VACCINES WORLD 2024 (Canada)
- Immunotherapy - Virology 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology 2024 (Austria)
- Inflammation and Immune Response - Virology 2024 (Austria)
- Innate and Adaptive Immune Responses - VACCINES WORLD 2024 (Canada)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- Innovative Immunotherapies - VACCINES WORLD 2024 (Canada)
- Next Generation Vaccines - VACCINE CONGRESS 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Novel Vaccine Platforms - VACCINE CONGRESS 2024 (Spain)
- One Health Approach - VACCINE CONGRESS 2024 (Spain)
- Paediatric Vaccination - Vaccine Immunology 2024 (France)
- Paediatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Public Health and Vaccination Programs - VACCINES WORLD 2024 (Canada)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Travel & Edible Vaccines - Vaccine Immunology 2024 (France)
- Vaccination Strategies for Vector-Borne Diseases - VACCINES WORLD 2024 (Canada)
- Vaccine Adjuvants - VACCINE CONGRESS 2024 (Spain)
- Vaccine Clinical Trials - VACCINE CONGRESS 2024 (Spain)
- Vaccine Delivery Systems - VACCINE CONGRESS 2024 (Spain)
- Vaccine Development - Virology 2024 (Austria)
- Vaccine Development and Design - VACCINES WORLD 2024 (Canada)
- Vaccine Development for Emerging Diseases - VACCINE CONGRESS 2024 (Spain)
- Vaccine Economics and Market Access - VACCINES WORLD 2024 (Canada)
- Vaccine Education and Advocacy - VACCINES WORLD 2024 (Canada)
- Vaccine Equity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Financing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Immunogenicity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Manufacturing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Policy and Regulation - VACCINE CONGRESS 2024 (Spain)
- Vaccine Production & Development - Vaccine Immunology 2024 (France)
- Vaccine Safety - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety and Adverse Event Monitoring - VACCINES WORLD 2024 (Canada)
- Vaccine Surveillance - VACCINE CONGRESS 2024 (Spain)
- Vaccines - Vaccine Immunology 2024 (France)
- Vaccines & Autism - Vaccine Immunology 2024 (France)
- Vaccines against Drugs - Vaccine Immunology 2024 (France)
- Vaccines against Infectious Diseases - Vaccine Immunology 2024 (France)
- Vaccines Epidemiology - VACCINE CONGRESS 2024 (Spain)
- Vaccines for Immune Mediated Diseases - Vaccine Immunology 2024 (France)
- Vaccines for Non-Communicable Diseases - VACCINES WORLD 2024 (Canada)
- Vaccines for Pregnant Women & Neonates - Vaccine Immunology 2024 (France)
- Vaccines for Unconventional Diseases - Vaccine Immunology 2024 (France)
- Vaccines Immunology - VACCINE CONGRESS 2024 (Spain)
- Vectors, Adjuvants & Delivery Systems - Vaccine Immunology 2024 (France)
- Viral Diagnostics - Virology 2024 (Austria)
- Viral Genomics and Evolution - Virology 2024 (Austria)
- Viral Immunology - Virology 2024 (Austria)
- Viral Pathogenesis - Virology 2024 (Austria)
- Viral Vaccines - Virology 2024 (Austria)